Despite the many advances in cardiovascular medicine, decisions concerning the
diagnosis, prevention, and treatment of left ventricular (LV) thrombus often remain …

Aims Left ventricular thrombus (LVT) increases the risk of thrombotic events and mortality.
Vitamin K antagonists (VKAs) used to treat LVT have several known risks, as a result of …

Meta-analysis may increase the risk of random errors. Trial sequential analysis (TSA) has
been developed to adjust for these random errors. We conducted TSA on the efficacy and …

For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K
antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism …

Left ventricular (LV) thrombus is a potentially serious complication affecting males and
females with ischemic and nonischemic cardiomyopathy—specifically, after acute …

Abstract Purpose Direct oral anticoagulants (DOACs) have been approved, for over a
decade, by both European and American medicine agencies, for treatment and prevention …

Abstract Background and Aims Current clinical guidelines for treating left ventricular
thrombus (LVT) are limited by inadequate evidence to inform the comparative efficacy of oral …

Background Direct oral anticoagulants are frequently used to treat post-myocardial infarction
(MI) left ventricular thrombus (LVT). This study was conducted to evaluate the efficacy and …

Patients with impaired left ventricular (LV) function can develop LV thrombus, a potentially
life‐threatening condition due to risk of stroke and embolization. Conventional treatment with …

Background There is no clear consensus on the optimal choice of anticoagulant in patients
with left ventricular thrombi (LVT). Given the potentially fatal complications associated with …